Tags

Type your tag names separated by a space and hit enter

[Immunity against SARS-CoV-2: walking to the vaccination].
Rev Esp Quimioter. 2020 Dec; 33(6):392-398.RE

Abstract

The coronavirus are a wide group of viruses among that the SARS-CoV-2 is included (family Coronaviridae, subfamily Coronavirinae, genus Betacoronavirus and subgenus Sarbecovirus). Its main structural proteins are the membrane (M), the envelope (E), the nucleocapsid (N) and spike (S). The immune response to SARS-CoV-2 involves the cellular and the humoral sides, with neutralizing antibodies fundamentally directed against the S antigen. Although the seroprevalence data are frequently assumed as protection markers, no necessarily they are. In Spain, it is estimated that, to assure the herd immunity, at least four-fifths of the population should be immunoprotected. Due the high fatality rate of COVID-19, the acquisition of the protection only by the natural infection it not assumable and other measures as the mass immunization are required. Currently, there are several vaccine prototypes (including life virus, viral vectors, peptides and proteins and nucleic acid) in different phase of clinical evaluation. Foreseeably, some of these news vaccines would be soon commercially available. In this text, aspects related to these issues are reviewed.

Authors+Show Affiliations

No affiliation info availableJuan Carlos Sanz Moreno, Unidad de Microbiología Clínica. Laboratorio Regional de Salud Pública de la Comunidad de Madrid. Dirección General de Salud Pública de la Comunidad de Madrid. Centro de Especialidades Médicas Vicente Soldevilla 2ª planta. C/ Sierra de Alquife 8. Madrid 28053 Spain. juan.sanz@salud.madrid.org.

Pub Type(s)

Journal Article
Review

Language

spa

PubMed ID

32935536

Citation

Rodríguez Hernández, C, and L Sanz Moreno. "[Immunity Against SARS-CoV-2: Walking to the Vaccination]." Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia, vol. 33, no. 6, 2020, pp. 392-398.
Rodríguez Hernández C, Sanz Moreno L. [Immunity against SARS-CoV-2: walking to the vaccination]. Rev Esp Quimioter. 2020;33(6):392-398.
Rodríguez Hernández, C., & Sanz Moreno, L. (2020). [Immunity against SARS-CoV-2: walking to the vaccination]. Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia, 33(6), 392-398. https://doi.org/10.37201/req/086.2020
Rodríguez Hernández C, Sanz Moreno L. [Immunity Against SARS-CoV-2: Walking to the Vaccination]. Rev Esp Quimioter. 2020;33(6):392-398. PubMed PMID: 32935536.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Immunity against SARS-CoV-2: walking to the vaccination]. AU - Rodríguez Hernández,C, AU - Sanz Moreno,L, Y1 - 2020/09/11/ PY - 2020/9/17/pubmed PY - 2020/12/15/medline PY - 2020/9/16/entrez KW - SARS-CoV2 KW - immunity KW - vaccination SP - 392 EP - 398 JF - Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia JO - Rev Esp Quimioter VL - 33 IS - 6 N2 - The coronavirus are a wide group of viruses among that the SARS-CoV-2 is included (family Coronaviridae, subfamily Coronavirinae, genus Betacoronavirus and subgenus Sarbecovirus). Its main structural proteins are the membrane (M), the envelope (E), the nucleocapsid (N) and spike (S). The immune response to SARS-CoV-2 involves the cellular and the humoral sides, with neutralizing antibodies fundamentally directed against the S antigen. Although the seroprevalence data are frequently assumed as protection markers, no necessarily they are. In Spain, it is estimated that, to assure the herd immunity, at least four-fifths of the population should be immunoprotected. Due the high fatality rate of COVID-19, the acquisition of the protection only by the natural infection it not assumable and other measures as the mass immunization are required. Currently, there are several vaccine prototypes (including life virus, viral vectors, peptides and proteins and nucleic acid) in different phase of clinical evaluation. Foreseeably, some of these news vaccines would be soon commercially available. In this text, aspects related to these issues are reviewed. SN - 1988-9518 UR - https://www.unboundmedicine.com/medline/citation/32935536/[Immunity_against_SARS_CoV_2:_walking_to_the_vaccination]_ DB - PRIME DP - Unbound Medicine ER -